# reload+after+2024-01-21 17:45:41.034955
address1§99 High Street
address2§26th Floor
city§Boston
state§MA
zip§02110
country§United States
phone§857 449 2244
website§https://www.karunatx.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease. The company also focuses on developing other muscarinic-targeted drug candidates; and intends to develop lead candidature TRPC4/5 and KAR-2618 for the treatment of mood and anxiety disorders. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.
fullTimeEmployees§210
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Andrew Craig Miller', 'age': 41, 'title': 'Co-Founder & COO', 'yearBorn': 1982, 'fiscalYear': 2022, 'totalPay': 835400, 'exercisedValue': 2483282, 'unexercisedValue': 68666400}, {'maxAge': 1, 'name': 'Dr. Steven M. Paul M.D.', 'age': 72, 'title': 'President of Research and Development, Chief Scientific Officer & Director', 'yearBorn': 1951, 'fiscalYear': 2022, 'totalPay': 1318150, 'exercisedValue': 0, 'unexercisedValue': 415439808}, {'maxAge': 1, 'name': 'Dr. Stephen K. Brannan', 'age': 67, 'title': 'Chief Medical Officer', 'yearBorn': 1956, 'fiscalYear': 2022, 'totalPay': 751750, 'exercisedValue': 17049636, 'unexercisedValue': 12357927}, {'maxAge': 1, 'name': 'Mr. William  Meury', 'age': 55, 'title': 'President, CEO & Director', 'yearBorn': 1968, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Jason Parker Brown', 'title': 'Chief Financial Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Alexis  Smith', 'title': 'Vice President of Corporate Affairs & Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Mia  Kelley J.D.', 'title': 'Vice President of Legal Affairs', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Frank  Truslow', 'title': 'Senior Vice President of Corporate Development', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Jonathan  Rosin', 'title': 'Chief Human Resources Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Alan  Breier', 'title': 'Chair of Scientific Advisory Board & Chief Clinical Advisor', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§7
boardRisk§7
compensationRisk§10
shareHolderRightsRisk§8
overallRisk§9
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§1.195
priceToSalesTrailing12Months§2020.2041
currency§USD
dateShortInterest§1702598400
forwardEps§-11.17
pegRatio§0.32
exchange§NGM
quoteType§EQUITY
shortName§Karuna Therapeutics, Inc.
longName§Karuna Therapeutics, Inc.
firstTradeDateEpochUtc§1561728600
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§94ef712e-8642-32d7-afd7-4c98c2966391
gmtOffSetMilliseconds§-18000000
targetHighPrice§330.0
targetLowPrice§245.0
targetMeanPrice§317.81
targetMedianPrice§330.0
recommendationMean§2.7
recommendationKey§hold
numberOfAnalystOpinions§16
quickRatio§27.396
grossMargins§1.0
ebitdaMargins§0.0
trailingPegRatio§None
